Soluble F proteins exacerbate pulmonary histopathology after vaccination upon respiratory syncytial virus challenge but not when presented on virus-like particles. Issue 11 (2nd November 2017)

• Record Type: Journal Article
• Authors: Lee, Youri; Lee, Young-Tae; Ko, Eun-Ju; Kim, Ki-Hye; Hwang, Hye Suk; Park, Soojin; Kwon, Young-Man; Kang, Sang Moo
• Is Part Of: Human vaccines & immunotherapeutics. Volume 13:Issue 11(2017)
• Page Start: 2594
• Page End: 2605
• Publication Date: 2017-11-02
• Subjects: enhanced disease -- F protein -- respiratory syncytial virus -- safety -- virus-like particle; Vaccines -- Periodicals; 615.372
• DOI: 10.1080/21645515.2017.1362514
• Languages: English
• ISSNs: 2164-5515

Abstract

ABSTRACT: Respiratory syncytial virus (RSV) fusion (F) protein is suggested to be a protective vaccine target although its efficacy and safety concerns remain not well understood. We investigated immunogenicity, efficacy, and safety of F proteins in a soluble form or on virus-like particle (F-VLP). F VLP preferentially elicited IgG2a antibody and T helper type 1 (Th1) immune responses whereas F protein induced IgG1 isotype and Th2 responses. Despite lung viral clearance after prime or prime-boost and then RSV challenge, F protein immune mice displayed weight loss and lung histopathology and high mucus production and eosinophils. In contrast, prime or prime-boost vaccination of F VLP induced effective protection, prevented infiltration of eosinophils and vaccine- enhanced disease after challenge. This study provides insight into developing an effective and safe RSV vaccine candidate.